More focus is needed on the risk of activation or stimulation as described in the new class of warnings from the Food and Drug Administration, including anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania and other unusual changes of behavior, worsening of depression and suicidal ideation. […]
Read More
Information on antidepressant-induced akathisia comes to light with court filing in Lacuzong case. courtfiling.pbreggin.2006.pdf
Read More
Paxil Special Report II: Second special report in a series providing excerpts from Dr. Breggin’s 1999 product liability report in the CA case of Lacuzong v. GlaxoSmithKline alleging that Paxil (paroxetine) caused a double murder and suicide. Ethical Psychology and Psychiatry 8 (2006) 91-100. Peter Breggins Paxil special report II.pdf
Read More
Paxil Special Report III: The third special report in a series providing excerpts from Dr. Breggin’s 1999 product liability report in the CA case of Lacuzong v. GlaxoSmithKline, alleging that Paxil (paroxetine) caused a double murder and suicide. Ethical Human Psychology and Psychiatry 8 (2006) 255-263. Peter Breggins Paxil Special […]
Read More
By Peter R. Breggin, M.D. January 12, 2006 A report in the January 9th Newsweek asks about retired star baseball pitcher Jeff Reardon, “Did drugs make a star hurler rob a jewelry shop?” The story has been all over the media. Apparently taking numerous antidepressants, Jeff Reardon, a wealthy […]
Read More
“Recent regulatory changes in antidepressant labels: Implications for activation (stimulation) in clinical practice.” Primary Psychiatry, 13, 57-60, 2006. recentregulatory.pbreggin.2006.pdf
Read More